Cagrilintide/Tre -5MG

TheraTide USA

$115.99
Availability:
In Stock
Adding to cart… The item has been added
 

Compound: Cagrilintide TRE, a long-acting acylated analog of amylin (AMYR/CTR agonist)

Form: ≥99% purity lyophilized, US-made peptide :contentReference[oaicite:1]{index=1}

For research use only—NOT for human or veterinary use.

Batch tested ≥99% purity by third-party lab. COAs available upon request—email providers@theratideusa.com.

  • Weight loss in humans: Phase II showed once-weekly dosing led to average 6–10% weight loss vs ~3% with placebo; 4.5 mg dose outperformed liraglutide 3 mg :contentReference[oaicite:2]{index=2}.
  • Mechanism: Activates amylin and calcitonin receptors to suppress appetite via satiety and hunger pathways :contentReference[oaicite:3]{index=3}.
  • CagriSema combo: Combined with semaglutide, CagriSema in Phase III produced ~22–23% weight loss over 68 weeks, exceeding monotherapy arms :contentReference[oaicite:4]{index=4}.
  • Diabetes & metabolic support: Improved glycemic control and weight loss demonstrated in type 2 diabetes (CagriSema trials) :contentReference[oaicite:5]{index=5}.
  • Safety: Generally well-tolerated; GI side effects (nausea, constipation, diarrhea) and injection-site reactions most common :contentReference[oaicite:6]{index=6}.

All data from clinical trials (Phase II/III); preclinical metabolic and obesity studies support human findings.

What is it studied for?
Made for obesity and type 2 diabetes via appetite suppression and improved satiety :contentReference[oaicite:7]{index=7}.

How does it work?
Targets amylin and calcitonin receptors to slow gastric emptying and enhance fullness :contentReference[oaicite:8]{index=8}.

What dose is used?
Clinical trials have used 0.3–4.5 mg weekly; higher doses yield greater weight loss :contentReference[oaicite:9]{index=9}.

What about side effects?
Mostly mild GI (nausea, constipation, diarrhea) and injection-site reactions; symptoms abate over time :contentReference[oaicite:10]{index=10}.

Storage?
Store lyophilized at ≤–20 °C; reconstitute freshly before use; keep away from light.

For laboratory research only—not for human or veterinary use, nor as a dietary supplement.

Safety: Handle under professional lab protocols with proper gear.

FDA Notice: These statements have not been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.

All products offered by TheraTide USA are strictly intended for research and development purposes only.

None of the statements on this website have been evaluated by the U.S. Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease.

TheraTide USA is a research chemical supplier. We are not a compounding pharmacy or a chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Logo

You must be 21+ to enter

This site contains research products intended only for adult use.